# Norris Medicine (NSE: NORRIS) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/NORRIS · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹14 Cr, it ranks 3771st by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was 0.0% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹1 Cr (−48.2% year on year) and net profit ₹0 Cr, on a standalone basis. Promoters held 34.01% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹14 Cr |
| ROE | 0.0% (FY25) |
| ROCE | −20.2% (FY25) |
| Debt to equity | -1.45 |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹1 Cr | −48.2% | ₹0 Cr | — | ₹0.05 |
| Q3 FY26 | ₹3 Cr | +194.6% | ₹1 Cr | — | ₹0.70 |
| Q2 FY26 | ₹2 Cr | +57.5% | −₹1 Cr | — | −₹0.72 |
| Q1 FY26 | ₹1 Cr | +102.8% | −₹0 Cr | — | −₹0.31 |
| Q4 FY25 | ₹3 Cr | +82.6% | −₹0 Cr | −235.3% | −₹0.23 |
| Q3 FY25 | ₹1 Cr | +70.8% | −₹0 Cr | — | −₹0.28 |
| Q2 FY25 | ₹1 Cr | −50.4% | −₹0 Cr | — | −₹0.36 |
| Q1 FY25 | ₹1 Cr | −24.2% | −₹0 Cr | — | −₹0.37 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹6 Cr | −₹1 Cr |
| FY24 | ₹6 Cr | −₹1 Cr |
| FY23 | ₹8 Cr | −₹2 Cr |
| FY22 | ₹9 Cr | −₹3 Cr |
| FY21 | ₹12 Cr | −₹5 Cr |
| FY20 | ₹8 Cr | −₹3 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 34.01%
- Domestic institutions: 0.07%
- Non-institutions: 65.92%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Family Care Hos](https://app.pivotnow.in/stock/FAMILYCARE) | — | ₹16 Cr | — | — |
| [Colinz Labs](https://app.pivotnow.in/stock/COLINZ) | — | ₹15 Cr | — | — |
| [Starsource Mult](https://app.pivotnow.in/stock/STARSOURCE) | — | ₹14 Cr | — | — |
| [Dolphin Medical](https://app.pivotnow.in/stock/DOLPHMED) | — | ₹12 Cr | — | — |
| [ORTIN GLOBAL](https://app.pivotnow.in/stock/ORTINGLOBE) | ₹13.53 | ₹11 Cr | — | — |
| [Beryl Drugs](https://app.pivotnow.in/stock/BERLDRG) | — | ₹11 Cr | — | — |

## Questions and answers

### What is the market cap of Norris Medicine?

Norris Medicine's market capitalisation is ₹14 Cr (₹14 Cr) at the 22 Oct 2026 close, ranking 3771st among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Norris Medicine?

Return on equity was 0.0% in FY25 and return on capital employed was −20.2% in FY25 (standalone figures).

### Is Norris Medicine a debt-free company?

Norris Medicine is close to debt-free: its debt-to-equity ratio was -1.45 in FY25.

### What were Norris Medicine's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Norris Medicine reported revenue of ₹1 Cr, −48.2% year on year, and net profit of ₹0 Cr.

### What is the shareholding pattern of Norris Medicine?

As of 30 Jun 2026: promoters 34.01%, domestic institutions 0.07%, non-institutions 65.92%.

### Who are Norris Medicine's competitors?

The listed Pharma & Healthcare companies closest to Norris Medicine by market cap are Family Care Hos, Colinz Labs, Starsource Mult, Dolphin Medical, ORTIN GLOBAL and Beryl Drugs.

### Is Norris Medicine a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Norris Medicine's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on NORRIS against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.